CQP(SZ:000950)2025-09-04 08:14Group 1: Financial Performance - The company's operating revenue for the first half of 2025 reached 41.188 billion yuan, representing a year-on-year growth of 3.54% [2] - The net profit attributable to shareholders was 2.82 billion yuan, with a year-on-year increase of 18.56% [2] - The net profit excluding non-recurring items was 2.77 billion yuan, showing a year-on-year growth of 26.68% [2] Group 2: Third-party Storage and Distribution Business - The revenue from the third-party storage and distribution business exceeded 15 million yuan during the reporting period, expanding into various fields including traditional Chinese medicine, e-commerce, medical devices, and radiopharmaceuticals [2] Group 3: Narcotic and Psychotropic Drugs - The sales of narcotic and psychotropic drugs amounted to 1.736 billion yuan, reflecting a year-on-year increase of 19.07% [3] - The company is one of three national wholesale enterprises for narcotic drugs, with a sales network covering all 31 provinces and regions [3] Group 4: Financial Cost Management - Financial costs decreased significantly, with a reduction of 165 million yuan, marking a year-on-year decline of 30.35% [3] - The financial cost rate reached a five-year low, with expectations for further reductions in the future [3] Group 5: Collaboration with General Technology Group - The company accelerated collaboration with medical institutions under the General Technology Group, opening 104 accounts in 22 provinces, including 89 grade hospitals [3] - A strategic cooperation agreement was signed with General Health and China Pharmaceutical to enhance resource integration and optimize supply chain management [3]